China Medical System Holdings Limited (HKG:0867)
Hong Kong
· Delayed Price · Currency is HKD | Market Cap | 20.06B |
| Revenue (ttm) | 7.54B |
| Net Income (ttm) | 1.49B |
| Shares Out | 2.42B |
| EPS (ttm) | 0.61 |
| PE Ratio | 13.59 |
| Forward PE | 9.93 |
| Dividend | 0.42 (5.06%) |
| Ex-Dividend Date | Aug 29, 2024 |
| Volume | 6,909,406 |
| Average Volume | 4,357,629 |
| Open | 7.95 |
| Previous Close | 8.33 |
| Day's Range | 8.18 - 8.46 |
| 52-Week Range | 6.23 - 13.16 |
| Beta | 0.89 |
| RSI | 70.55 |
| Earnings Date | Mar 14, 2025 |
About HKG:0867
China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People’s Republic of China. Its products include VALTOCO, a diazepam nasal spray to treat seizure clusters; Plendil for the treatment of hypertension and stable angina pectoris; XinHuoSu to treat acute heart failure; Deanxit for mild-to-moderate depression, anxiety, and psychosomatic affections; METOJECT, a methotrexate injection for recalcitrant disabling psoriasis; and Ursofalk for the treatment of ch... [Read more]
Financial Performance
In 2023, HKG:0867's revenue was 8.01 billion, a decrease of -12.43% compared to the previous year's 9.15 billion. Earnings were 2.40 billion, a decrease of -26.33%.
Financial numbers in CNY Financial StatementsNews
Alpha Cognition Inks $44 Million Licensing Pact For Its Alzheimer's Drug In China
On Wednesday, Alpha Cognition Inc. (NASDAQ: ACOG) and China Medical System Holdings Limited announced an exclusive licensing agreement for the development, manufacturing, and commercialization of Zun...